Stay informed with the latest developments in medicine and public health policy. For daily updates, subscribe to STAT’s Morning Rounds.
The global health community is mourning the loss of a cultural icon, Dolly Parton. While celebrated for her incomparable musical legacy and philanthropic reach, her impact extended into the halls of science. Parton was a vocal advocate for medical research, most notably providing significant funding that supported the development of the Moderna Covid-19 vaccine. Her passing serves as a poignant reminder of how public figures can serve as catalysts for scientific progress.
Beyond this loss, the week has been marked by a series of critical health developments, ranging from the return of preventable infectious diseases to the systemic instability of employer-sponsored insurance and groundbreaking research into the long-term benefits of vaccination.
The Resurgence of Measles: A Public Health Warning
In a somber development for public health, the Pennsylvania Department of Health has confirmed two "measles-associated deaths" within the state. These represent the first fatalities attributed to the disease in the United States for 2026, and the first such cases in Pennsylvania in over three decades.
Chronology and Context
The return of measles—a disease once declared eliminated in the U.S.—has been a slow-moving crisis. Last year, the nation recorded three measles-related deaths, a stark increase from the near-zero baseline of the early 2000s. The two Pennsylvania individuals were reportedly unvaccinated, highlighting the persistent vulnerability of those who remain unprotected against highly infectious, vaccine-preventable diseases.
Shifting Demographics of Infection
While historical data focused on the risks to pediatric populations, the landscape is shifting. Helen Branswell’s reporting for STAT in 2023 identified a burgeoning crisis: adults are becoming increasingly susceptible to measles. As the first generation of children whose parents opted out of childhood vaccination schedules enters adulthood, the pool of unprotected adults is expanding. This creates a new, complex vector for transmission that public health officials fear could ignite larger, more difficult-to-contain outbreaks in the coming years.
The Corporate Healthcare Crisis: Costs Outpacing Predictions
A new survey from the Business Group on Health paints a grim picture for the future of employer-sponsored insurance. Despite the perceived sophistication of large corporate entities, the financial burden of providing healthcare to employees is becoming increasingly untenable.
Supporting Data
The survey, which polled 127 large employers—half of which employ at least 25,000 workers—reveals that health care spending between 2023 and 2025 grew significantly faster than initial projections. The data for the upcoming two-year period is even more concerning:
- 2026 Projected Cost Increase: 8.5%
- 2027 Projected Cost Increase: 9.2%
These figures represent the growth in costs before any plan design changes or benefit reductions are implemented by employers.
Official Responses and Implications
Ellen Kelsay, CEO of the Business Group on Health, characterized the inability of corporations to predict these costs as a symptom of a larger, systemic malaise within the American healthcare apparatus.
"Employers’ ability to accurately predict their health care costs is not just a budgeting problem," Kelsay stated during a recent press briefing. "It’s emblematic of a bigger picture issue with the overall health care system."
While small businesses have been dropping health insurance coverage at record rates, large corporations remain committed to offering benefits as a competitive necessity. However, Kelsay warned that the current volatility is unsustainable. She advised employers to critically evaluate whether their current vendors, consultants, and insurance carriers are delivering "meaningful value" or simply profiting from an opaque, inefficient system.
Medical Breakthroughs: The Shingles Vaccine as a Multi-System Shield
Researchers at Oxford University have provided compelling new evidence regarding the potential systemic benefits of the modern shingles vaccine, Shingrix. Building on a 2024 study that linked the vaccine to a lower incidence of dementia, new findings suggest the shot may also significantly reduce the risk of cardiovascular disease.
A Natural Experiment
The study employed a "natural experiment" methodology, comparing the health outcomes of individuals who received the vaccine prior to its formal approval against those who received it afterward. This approach allowed researchers to isolate the impact of the vaccine while accounting for other variables.
"We are keen to see results from randomized controlled trials, and one of them is already underway," said study co-author Maxime Taquet. "If these results are confirmed, Shingrix could prevent hundreds of thousands of cardiovascular events in the USA alone, and may be the first vaccine that protects both the heart and the brain."
The implication is that the vaccine may work by reducing systemic inflammation or through other biological pathways that prevent the degradation of both neurological and vascular health.
The Financialization of Women’s Health
The discourse surrounding women’s health is undergoing a profound shift, moving from a niche area of medical research to a prioritized investment category.
The Shift in Strategy
For decades, women’s health research—covering conditions that affect only women, affect them differently, or affect them disproportionately—languished in the shadow of federal funding cuts. Following the termination of various federal grants during the Trump administration, the sector faced a "funding winter."
However, a new wave of venture capital is attempting to fill this void. Elizabeth Bailey, co-founder of Foreground Capital, notes that the current environment is the most dynamic she has seen in two decades. "People are now talking about [women’s health] as an investment category," Bailey observed. This "reverse-pitch" approach seeks to prove that investing in women’s health is not only a moral imperative but a profitable market strategy, targeting long-neglected areas like endometriosis and osteoporosis.
Post-Dobbs: The Gap Between Predictions and Reality
Four years after the overturning of Roe v. Wade, the reality of the post-Dobbs landscape remains a point of intense scrutiny. Reproductive biologist David N. Hackney recently reflected on the discrepancies between initial expert predictions and current data.
Expectations vs. Observed Data
Many experts initially predicted a sharp, predictable decline in abortion rates, accompanied by a spike in infant and maternal mortality, alongside a mass exodus of medical professionals from states with restrictive laws. While the situation is volatile, the anticipated catastrophic metrics have not materialized in the exact ways many predicted.
Ethical Imperatives
Hackney argues in a recent essay that obsessing over the data points can distract from the core issue. He posits that the "foundational ethical assault" of abortion bans remains the primary concern, regardless of the fluctuating data.
"When arguments are based on consequences, we then argue about data when we should be fighting for freedoms," Hackney writes. His perspective serves as a call to action for advocates to remain focused on bodily autonomy and human rights as the central pillars of the debate, rather than getting mired in the "consequence-based" arguments that have dominated the media landscape since 2022.
Summary of Implications
The convergence of these stories highlights a nation at a crossroads. The resurgence of measles points to a breakdown in the public health social contract; the corporate healthcare crisis underscores the economic fragility of the employer-based model; and the promise of the shingles vaccine and the new investment in women’s health represent the optimistic, innovative side of modern medicine.
As we look toward the remainder of the year, these themes—the cost of care, the resurgence of old threats, and the potential for new medical breakthroughs—will continue to define the health policy agenda. Whether in the boardroom or the laboratory, the need for transparency, systemic reform, and a commitment to evidence-based policy has never been more urgent.
